Literature DB >> 11216448

Intrathecal cannabinoid administration suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in rat spinal cord: comparison with morphine.

A G Hohmann1, K Tsou, J M Walker.   

Abstract

AIM: To determine whether cannabinoids suppress noxious stimulus-evoked Fos protein-like immunoreactivity (FLI) through direct actions at the spinal level.
METHODS: Rats were implanted with intrathecal (ith) catheters at least one week prior to evaluation in the formalin test. Effects of the cannabinoid agonist, CP55,940 (80 micrograms ith) on formalin pain and FLI in rat spinal cord were compared with that of the prototypic narcotic analgesic, morphine (20 micrograms ith). CP55,940 suppressed pain behavior and FLI induced by intraplantar formalin. The cannabinoid suppressed Fos in the neck region of the dorsal horn and in the ventral horn, but not in the nucleus proprius. The efficacy of the cannabinoid in suppressing FLI in these laminae and pain behavior was comparable to morphine administered via the same route. However, only morphine suppressed FLI in the superficial dorsal horn relative to vehicle treatment.
CONCLUSION: Cannabinoids suppress nociceptive processing, in part, through actions at the spinal level. However, morphine showed greater potency and efficacy than CP55,940 in suppressing formalin-induced FLI following spinal administration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11216448

Source DB:  PubMed          Journal:  Zhongguo Yao Li Xue Bao        ISSN: 0253-9756


  8 in total

Review 1.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

2.  Attenuation of morphine antinociceptive tolerance by cannabinoid CB1 and CB2 receptor antagonists.

Authors:  Ahmet Altun; Kemal Yildirim; Ercan Ozdemir; Ihsan Bagcivan; Sinan Gursoy; Nedim Durmus
Journal:  J Physiol Sci       Date:  2015-04-18       Impact factor: 2.781

Review 3.  Endocannabinoid mechanisms of pain modulation.

Authors:  Andrea G Hohmann; Richard L Suplita
Journal:  AAPS J       Date:  2006-11-17       Impact factor: 4.009

4.  The periaqueductal gray contributes to bidirectional enhancement of antinociception between morphine and cannabinoids.

Authors:  Adrianne R Wilson-Poe; Edvinas Pocius; Melissa Herschbach; Michael M Morgan
Journal:  Pharmacol Biochem Behav       Date:  2012-10-10       Impact factor: 3.533

5.  Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain.

Authors:  C Z Zhu; J P Mikusa; Y Fan; P R Hollingsworth; M Pai; P Chandran; A V Daza; B B Yao; M J Dart; M D Meyer; M W Decker; G C Hsieh; P Honore
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

6.  Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception.

Authors:  Adrianne R Wilson; Lauren Maher; Michael M Morgan
Journal:  Neuropharmacology       Date:  2008-08-05       Impact factor: 5.250

7.  The naked mole-rat has a functional purinergic pain pathway despite having a non-functional peptidergic pain pathway.

Authors:  Brigitte M Browe; Abigail R Olsen; Cesar Ramirez; Rebecca H Rickman; Ewan St John Smith; Thomas J Park
Journal:  Neurobiol Pain       Date:  2020-05-11

8.  Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies.

Authors:  David P Finn; Simon Haroutounian; Andrea G Hohmann; Elliot Krane; Nadia Soliman; Andrew S C Rice
Journal:  Pain       Date:  2021-07-01       Impact factor: 7.926

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.